Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Pre-concentration can reduce the total production costs in the pharmaceutical industry. Organic solvent forward osmosis (OSFO) is a suitable pre-concentration method because of its nonthermal nature, low capital cost, and potential for achieving high-degree concentrations. In a previous study, we first demonstrated a high-degree OSFO concentration. Sucrose octaacetate (SoA) in MeOH was concentrated to 52 wt% using polyethylene glycol (PEG)-400 as the osmotic agent, but the concentrated solution had a concentration of 17% PEG-400 because of the reverse solute flux. This result does not meet the typical purity standards required for pharmaceutical production, indicating the need to determine a suitable osmotic agent that can be used for practical purposes. This study proposes a practical osmotic agent for OSFO pre-concentration. First, osmotic agents were screened from a practical perspective. Polypropylene glycol (PPG)-400 was selected, owing to its low toxicity, good solubility, and low viscosity. Subsequently, the OSFO concentration was demonstrated using PPG-400 as the osmotic agent. SoA in MeOH was concentrated from 9.4 wt% to 48 wt%. The final feed solution contained only 0.04 wt% PPG-400. This result is the first demonstration of successful pharmaceutical pre-concentration using OSFO that satisfies the typical purity requirement in pharmaceutical production.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11433671 | PMC |
http://dx.doi.org/10.3390/membranes14090187 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!